Lyra Therapeutics, Inc. LYRA
0.20
0.17
566.67%
as of 25 Sep
- Market cap
- $870.0K
- P/E
- 0.0×
Follow LYRA
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | — | — | 0.00 | 68.54 | 166.23 | 8.76 | 12.02 |
P/FCF ratio |
— | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | (1.06) | — | — | (5.01) | (7.68) | (13.59) | (1.18) | (0.79) |
P/B ratio |
— | 0.00 | — | — | 1.65 | 1.16 | 2.90 | 1.16 | 0.00 |
Price to Tangible BV |
— | 0.00 | — | — | 1.65 | 1.16 | 2.90 | 1.16 | 0.00 |
EV/Sales |
— | 0.00 | — | — | 0.00 | (3.28) | 100.28 | (17.69) | (27.91) |
EV/EBITDA |
— | 1.81 | — | — | 0.00 | 0.08 | 0.00 | 0.28 | 0.36 |
EV/Operating CF |
— | 2.10 | — | — | (0.42) | 0.10 | (2.47) | 0.39 | 0.39 |
EV/FCF |
— | 2.07 | — | — | (0.37) | 0.10 | (2.43) | 0.38 | 0.38 |
Quick Ratio |
— | 12.27 | 1.88 | 15.27 | 2.51 | 6.77 | 5.24 | 3.21 | 1.67 |
Current Ratio |
— | 12.72 | 1.94 | 15.54 | 2.63 | 6.97 | 5.35 | 3.41 | 1.71 |
Net Debt/EBITDA |
— | 3.33 | 0.59 | 3.37 | 1.07 | 1.76 | 1.46 | 0.41 | 0.52 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.10 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 |
Operating CF/Net income |
— | 1.09 | 0.84 | 0.96 | 0.59 | 0.78 | 1.01 | 0.75 | 1.00 |
Capex/Depreciation |
— | 0.00 | (7.81) | (18.68) | (3.38) | (0.29) | 0.33 | 1.30 | (0.21) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 5.30% | 14.15% | 90.60% | (79.98%) | (96.08%) | (73.67%) | (184.99%) | (6,594.98%) | |
| — | (48.19%) | (80.88%) | (46.20%) | (64.13%) | (67.07%) | (49.63%) | (89.43%) | (56.45%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (26.48%) | (316.74%) | (30.23%) | (127.32%) | (62.39%) | (71.83%) | (293.84%) | (370.71%) |
Average Days of Receivables |
— | 49.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 399.92% | 0.00% | 0.00% | 10,418.95% | 2,846.44% | 3,082.73% | 2,853.06% | 4,625.88% |
Selling, General and Administrative Expense of Revenue |
— | 277.01% | 0.00% | 0.00% | 4,984.56% | 1,288.04% | 1,223.17% | 1,206.06% | 2,899.50% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 971.93% | 399.63% | 377.86% | 437.81% | 586.68% |
Graham Net Nets |
— | 6.60 | — | — | 0.48 | 0.77 | 0.20 | (0.87) | (6.39) |
Graham Number |
— | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 54.53 |
Earnings Yield |
— | (421.93%) | — | — | (76.83%) | (68.14%) | (24.81%) | (692.83%) | (621.75%) |
Free Cash Flow Yield |
— | (349.82%) | — | — | (51.59%) | (46.61%) | (24.85%) | (538.45%) | (604.17%) |
Revenue per Share |
— | 0.10 | 0.00 | 0.00 | 1.10 | 2.25 | 1.56 | 1.18 | 0.26 |
Operating CF per Share |
— | (0.51) | (3,438.50) | (123.07) | (99.42) | (71.75) | (63.55) | (53.77) | (18.58) |
Capex per Share |
— | 0.00 | (52.75) | (10.33) | (13.03) | (0.27) | (1.05) | (1.80) | (0.06) |
Free Cash Flow per Share |
— | (0.51) | (3,491.25) | (133.40) | (112.46) | (72.02) | (64.60) | (55.57) | (18.65) |
Cash per Share |
— | 1.85 | 2,452.00 | 434.19 | 176.15 | 161.89 | 103.16 | 31.17 | 10.23 |
Shareholders Equity per Share |
— | 1.80 | 1,832.00 | 433.60 | 132.14 | 133.54 | 89.77 | 8.90 | (6.90) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 1.80 | 1,832.00 | 433.60 | 132.14 | 133.54 | 89.77 | 8.90 | (6.90) |
Free Cash Flow |
— | (6.64) | (13.96) | (22.92) | (29.20) | (43.55) | (64.35) | (72.35) | (28.96) |
Working Capital |
— | 22.97 | 4.91 | 71.03 | 29.67 | 86.36 | 85.22 | 30.39 | 6.75 |
Capital Expenditures |
— | (0.04) | (0.21) | (1.77) | (3.38) | (0.16) | (1.05) | (2.34) | (0.10) |
Net Current Asset Value |
— | 22.85 | 2.48 | 69.58 | 27.37 | 71.62 | 51.64 | (11.73) | (30.55) |
EV/EBIT |
— | 1.81 | — | — | 0.00 | 0.08 | 0.00 | 0.28 | 0.36 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 11.88 | 0.12 | 0.67 | 1.52 | 0.25 |
Net Profit Margin |
— | (491.16%) | 0.00% | 0.00% | (15,267.72%) | (4,055.61%) | (4,023.11%) | (6,090.94%) | (7,266.08%) |
Price to Operating Income |
— | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.80 | 0.11 | 0.04 | 0.22 | 0.26 | (1.58) | (1.29) | 0.44 |
Cash ROIC |
— | (14.30%) | (81.65%) | (15.63%) | (37.87%) | (25.54%) | (34.00%) | (136.89%) | (577.86%) |
Accounts Receivable Turnover |
— | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 0.85 | 0.85 | 1.00 | 2.02 | 2.87 | 2.87 | 2.16 | 0.92 |
Average Assets |
— | 12.68 | 20.16 | 47.90 | 67.85 | 82.42 | 126.28 | 104.47 | 51.23 |
Average Common Equity |
— | (115.21) | (115.21) | (24.42) | 54.40 | 57.54 | 85.09 | 50.51 | 0.44 |
Columns are period end dates